Table 3 ETS2 expression associated with the clinicopathological parameters in GC
From: lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p
Clinicopathological parameters | n | ETS2 Low (n%) | ETS2 High (n%) | P |
|---|---|---|---|---|
Gender | ||||
 Male | 55 | 11 (20.0) | 44 (80.0) | 0.800 |
 Female | 20 | 6 (30.0) | 14 (70.0) | |
Age (years) | ||||
 < 60 | 33 | 11 (33.3) | 22 (66.7) | 0.041* |
 ≥ 60 | 42 | 5 (11.9) | 37 (88.1) | |
Tumor diameter (cm) | ||||
 < 5 | 31 | 9 (29.0) | 22 (71.0) | 0.409 |
 ≥ 5 | 44 | 8 (18.2) | 36 (81.8) | |
Pathological grading | ||||
 I–II | 23 | 12 (52.2) | 11 (47.8) | 0.001** |
 III–IV | 52 | 5 (9.6) | 47 (90.4) | |
TNM staging | ||||
 T1–T2 | 15 | 7 (46.7) | 8 (53.3) | 0.023* |
 T3–T4 | 60 | 10 (16.7) | 50 (83.3) | |